Photo credit: www.investing.com
Applied BioCode Enhances Gastrointestinal Pathogen Testing with New Nucleic Acid Extraction Feature
SANTA FE SPRINGS, Calif.–Applied BioCode, a prominent player in the molecular diagnostics sector, has announced an important upgrade to its BioCode® Gastrointestinal Pathogen Panel (GPP). The enhancement introduces a nucleic acid extraction capability that integrates seamlessly with the ThermoFisher Scientific KingFisher Flex platform. This development is set to streamline workflows and enhance the efficiency of sample processing in clinical laboratories utilizing the BioCode® GPP.
The newly added extraction feature allows laboratories to operate more effectively, as it supports the detection of 17 major gastrointestinal pathogens. By combining the BioCode® GPP with the KingFisher Flex system, clinicians can expect a more efficient workflow that contributes to faster, more accurate diagnostic outcomes, ultimately benefiting patient care through timely information delivery.
Dr. Winston Ho, CEO and founder of Applied BioCode, emphasized the company’s dedication to providing versatile, high-quality solutions for molecular diagnostics. “Expanding our nucleic acid extraction options to include KingFisher Flex showcases our commitment to flexible testing workflows that adapt to the needs of our clinical lab partners, with the ultimate goal of improving patient outcomes,” he noted.
Versatility and Innovation in Pathogen Detection
The BioCode® GPP now stands out for its compatibility with various extraction platforms, affirming its position as one of the most adaptable panels available for detecting gastrointestinal pathogens in stool samples. This move aligns with Applied BioCode’s ongoing mission to innovate and respond to the increasing demands of healthcare providers, enabling laboratories to optimize their existing instruments while enhancing diagnostic capabilities.
Utilizing unique Barcoded Magnetic Bead (BMB) technology, the BioCode® GPP facilitates high-throughput molecular diagnostics. This technology provides a cost-effective, precise solution for clinical laboratories not only in the U.S. but around the world. The latest expansion in nucleic acid extraction will aid laboratories in refining their workflows, enhancing operational flexibility, and broadening diagnostic options.
About Applied BioCode
Applied BioCode is an in vitro diagnostics (IVD) company specializing in the development and commercialization of multiplex testing products. Their innovative approach combines digital barcoding with immuno- and molecular chemistry, resulting in the creation of bio-inspired Barcoded Magnetic Bead (BMB) technology. The company’s micro BMBs are designed to be checked with ease, allowing for the identification of up to 4,096 barcodes—ensuring clarity for biological targets.
Applied BioCode has received FDA 510K clearances for its 17-plex Respiratory Pathogen Panel (RPP) and 17-plex Gastrointestinal Pathogen Panel (GPP). Both panels are also CE-Marked for compliance with European regulations. Moreover, the company has been granted Emergency Use Authorization (EUA) from the FDA for its BioCode® SARS-CoV-2 Assay and related testing products. Additionally, Applied BioCode holds RUO (Research Use Only) designations for the BioCode® Fungal Panel and STI + Resistance Panel, and collaborates with various diagnostic companies targeting infectious diseases, autoimmune disorders, allergies, gut microbiome research, and veterinary diagnostics.
Emergency Use Authorizations and Regulatory Compliance
The BioCode® SARS-CoV-2 Flu Plus Assay, BioCode® SARS-CoV-2 Assay, and other related products are authorized solely for the detection of specific viral pathogens and are not approved for any other viruses. Their use is contingent upon the ongoing declaration that permits emergency use of in vitro diagnostics for COVID-19 detection, as laid out under relevant U.S. government regulations.
For further details about the newly added nucleic acid extraction capabilities of the BioCode® GPP or to explore more of Applied BioCode’s pioneering diagnostic solutions, interested parties can visit Applied BioCode’s official website.
View the original announcement at Business Wire.
Source
www.investing.com